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Hepatocellular carcinoma (HCC) is a very common neoplasia and there has been little improvement in 5tyear survival in the last 
two decades (with a median survival of less than 1 year 
in the United States or Europe) despite the developt
ment of new diagnostic techniques such as ultrasonogt
raphy, CT, MRI and angiography, and advancements in 
therapeutic modalities, such as surgical resection, rat
diofrequency ablation, percutaneous ethanol injection, 
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BACKGROUND AND OBJECTIVES: the failure of existing treatments for liver cancer has recently been attrib-
uted to the existence of cancer stem cells, which are difficult to kill using current drugs due to their chemoresis-
tant properties as well as their ability to stimulate neoangiogenesis. the aim of the current study was to evaluate 
in vitro the antitumor efficacy of arsenic trioxide in combination with conventional chemotherapy, as proposed 
by the concept of ”differentiation therapy” in anticancer research.
MATERIALS AND METHODS: Cancer stem cells showed enhanced chemoresistance to cancer drugs (carboplatin 
and doxorubicin) and had the ability to exclude rhodamine 123 dye, proving the existence of the multidrug resis-
tance efflux pump. arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified Piaf regi-
men with capecitabine replacing 5-fluorouracil. We also compared both cancer and normal stem cell lines with 
the hepG2 non-stem liver cancer cell line to investigate the differences between differentiated and more anaplastic 
cells. molecular characterization (immunocytochemistry and rt-PCr analysis) of all the cell lines was carried out. 
RESULTS: initially, the cells had a high proliferative potential, even when cultured in a medium supplemented 
with cytostatics, eliminated rhodamine 123 immediately in culture and also formed spheroids in suspension. 
the molecular characterization showed the expression of albumin, α1-antitrypsin, α-fetoprotein, citokeratin-18, 
telomerase, CD90 and CD133. Low concentrations of arsenic trioxide lead to morphologic differentiation and 
differentiation-associated cytochemical features, like increased sensitivity to cytostatic drugs.
CONCLUSION: our study suggests that arsenic trioxide sensitizes liver stem-like cancer cells to conventional 
chemotherapy. still, further studies on animal models will be needed before we implement this idea in human 
clinical trials.
transcatheter arterial chemoembolization, radiotherapy 
and intratarterial infusion via implantable drug delivery 
systems. HCC chemotherapy includes patients with 
advancedtstage tumors signified by portal vein invasion, 
metastasis or failure of other treatment options and is 
usually limited to persons with Eastern Cooperative 
Oncology Groups performance status of 0 to 2 and int
tact hepatic function (ChildtPugh A or early B). Even 
if the results are mainly palliative, combination therapy 
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may improve the response rate, and the main trends int
clude PIAF (cisplatin, doxorubicin, 5tfluorouracil and 
Interferon αt2b) and tyrosine kinase inhibitors.1,2 
  The failure of existing treatments for cancer has 
recently been attributed to the existence of cancer stem 
cells (CSCs), which are difficult to kill using current 
drugs due to their chemoresistant properties as well as 
their ability to stimulate neoangiogenesis. These propt
erties contribute to tumor recurrence and treatment 
resistance in advanced cases via activation of ABC transt
porters, as well as Notch and HedgehogtGli1 signaling 
pathways involved in selftrenewal and tumorigenicity.3 
The American Association for Cancer Research sugests 
that successful therapies should target CSCs by comt
pletely eliminating them via inhibition of the selftrenewt
ing stem cell state or by inducing differentiation of CSCs 
into nonttumorigenic cells, more sensitive to convent
tional therapy.4 The differentiation therapy hypothesis 
has recently been investigated by Ito et al, by using the 
inorganic arsenite, arsenic trioxide As2O3 (ATO), in 
the treatment of leukemia.5 ATO treatment significantly 
decreased the number of quiescent leukemia stem cells 
without inducing apoptosis, this result being confirmed 
by Kobayashi et al, who treated a patient with acute 
promyelocytic leukemia with arsenic plus conventional 
chemotherapy.6 If acute promyelocytic leukemia can be 
considered a model disease for anticancer research,7 we 
investigated the in vitro effects of low concentrations of 
ATO on CSCs isolated from solid tumors. 
MATERIALS AND METHODS 
Cell culture protocols
Cancer stem cells were isolated from a hepatocellular 
carcinoma biopsy, as previously described.3 CSCs, along 
with normal liver stem cells and the nontstem tumor 
cell line HepG2 (both kindly provided by the Professor 
Carmen Mihu, MD, PhD, Department of Histology, 
Iuliu Hatieganu University of Medicine and Pharmacy 
from Cluj Napoca, Romania) were maintained in Ham’s 
Ft12 and Dulbecco’s Modified Essential Medium at 1:1 
ratio, supplemented with 10% fetal calf serum (FCS), 
100 U/mL penicillin and 100 μg/mL streptomycin (all 
from Sigma Aldrich, St Louis, MO, USA) in a 37 °C 
humidified incubator with a mixture of 95% air and 
5% carbon dioxide. All experiments were performed on 
exponentially growing cells, with a doubling time of apt
proximately 24 to 36 hours.
Multidrug resistance assay
To assess the resistance of cells isolated from hepatocelt
lular carcinoma to chemotherapy, cells were seeded at 
3000 cells/well in 96twell plates. The culture media was 
DMEM/F12 supplemented with growth factors. Cancer 
stem cells were compared with HFL human lung fibrot
blasts (European Collection of Cell Cultures, Budapest, 
Hungary) and with MLS human ovarian tumor cells 
(courtesy of Dr Yael Schiffenbauer, Weizmann Institute 
of Science, Rehovot, Israel). Six hours later, all cells were 
treated with 5 μg/mL carboplatin and 5 μg/mL doxot
rubicin, concentrations higher than normally used in the 
clinic. After 24 and 48 hours, the relative cell number was 
determined by standard MTT assay. The MLS tumor 
ovarian cell line was used as another control of more dift
ferentiated tumor cells, apart from the HepG2 cell line.
Rhodamine 123 efflux assay
Hepatic cancer stem cells, MLS ovarian tumor cells and 
HFL human fibroblasts were seeded in specific culture 
media supplemented with FCS, nontessential amino 
acids, Ltglutamine and antibiotics, at 20×104 cells/mL. 
Cells were stained with 10 μM rhodamine 123 and then 
incubated for three hours at 37˚C and 7% CO2. After 
culture, all cell types were washed three times with 
PBS before intracellular fluorescence was measured ust
ing a BioTek Synergy 2 fluorescence microplate reader 
(Winooski, VT, USA).
Reactives and cytostatics
Arsenic trioxide (kindly provided by Professor Luminiţa 
SilaghitDumitrescu, Department of Inorganic 
Chemistry, BabeştBolyai University from Cluj Napoca, 
Romania) was added at a concentration of 0.5 μM prior 
to a tyrosine kinase inhibitor or to a slightly modiffied 
PIAF regimen with capecitabine replacing 5tfluorot
uracil, as according to the results of von Delius et al.8 
Sorafenib (a tyrosine kinase inhibitor) was used at a 
concentration of 4.6 μg/mL, doxorubicin at 0.5 μg/mL, 
cisplatin at 0.25 μg/mL, capecitabine at 30 μg/mL and 
interferon αt2b at 2 μg/mL, as used in the clinic.
Proliferation assay
Cell survival was assessed using the MTT assay, as previt
ously described.9 For 3t(4,5tdimethylthiazolt2tyl)t2,5t
diphenyltetrazolium bromide (MTT) assays, cells in 
monolayer culture were irradiated, incubated in DMEM 
media supplemented with 10% FCS, 100 U/mL penit
cillin and 100μg/mL streptomycin before being washed 
twice with phosphate buffer solution (PBS). Cells were 
then incubated with trypsintEDTA, resuspended in cult
ture medium with FCS, counted and plated in 100 μL 
media at 15×103 cells/well in 96twell microtiter plates. 
After 24 hours, cells were washed and treated with a 
concentration of 0.5 μM ATO before adding cytostatic 
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drugs. Absorbance of the MTT was measured at 492 
nm using the fluorescence microplate reader. 
Immunocytochemical staining
Hepatocellular carcinoma derived adherent cells were 
labeled with antithuman antibodies and fixed with 4% 
paraformaldehyde for 20 minutes. After blocking with 
Bovine Serum Albumine 10% (Sigma Aldrich), cells 
were incubated overnight with the following primary 
antibodies: CD90 and CD133, diluted 1:50. For cell 
staining with secondary antibodies, the protocols used 
fluorescein isothiocyanate (FITC) Goat antitmouse 
IgG and IgM phycoerythrin (PE) goat antitmouse IgG 
or Texas red goat antitmouse IgG. Cells nuclei were 
counterstained with 4,6tdiamidinot2tphenylindole 
(DAPI). The fluorescent cells were visualized with an 
inverted phase Zeiss Axiovert microscope using filtres 
of 488 546 and 340/360 nm.
RNA extraction and RT-PCR analysis
Total RNA was isolated from hepatic cancer stemt
like cells, from liver mesenchymal stem cells and 
from the HepG2 cell line. RNA isolation was pert
formed from subconfluent monolayers of adherent 
cells plated on 6twell dishes, using TRIzol Reagent 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. 1 μg of total RNA was 
used for reverse transcription with the ImProm 
Reverse Transcription System (Promega, Madison, 
WI, USA). Only mRNA was transformed into 
cDNA by using oligotdT primers in the reaction 
mixture, together with: AMV reversettranscript
tase 15 u/μg; buffer solution (10 mM TristHCl, 
pH=9.0; 50 mM KCl; 0,1% Triton Xt100); dNTP 
solution, 1 mM each; MgCl2 5mM; recombinant 
ribonuclease inhibitor 1 u/μL; ultrapure nucleaset
free water. The cDNA was amplifi ed using GoTaq 
PCR Core System II (Promega). The primers used 
were designed according to the corresponding hut
man genes, as shown in Table 1. Amplification react
tions were performed on a Techne TC3000 thermal 
cycler (Bibby Scientific Ltd, Staffordshire, United 
Kingdom) at 95°C for 30 seconds, 56°C for 1 mint
ute, and 72°C for 2 minutes for 40 cycles. The PCR 
products were then separated by electrophoresis on 
2% agarose gell and photographed with a UV transilt
luminator.
Statistical significance was evaluated using onet
way analysis of variance (ANOVA), with a 95% confit
dence level using GraphPad Prism 5 statistics program 
(GraphPad, San Diego, CA, USA). All experiments 
were performed in triplicate. 
Table 1. Primers used for the RT-PCR characterisation of the cancers stem-like cells, 
normal  hepatic stem cells and HepG2 hepatic tumor cells.
Primers Sequence (5’→3’) Size (bp)
Melting 
temperature 
(°C)
Oct-4 aggagtcccaggacatcaaagtcgtttggctgaataccttc 146 56
Rex-1 atggctatgtgtgctatgagcctcaacttcctagtgcatcc 447 50
TERT catcatcaaaccccagaacaccaaacagcttgttctccatgt 371 55
Nanog attataaatctagagactccagtcctgaataagcagatccatg 407 52
Sox-2 aagcgctttttttgatcctgattcaccacaccatgaaggcattcatg 363 57
β2-
microglobulin
actccaaagattcaggtttactc
catgatgctgcttacatgtc 302 52
HLA-DRα ttgaagaatttggacgatttgaaactcccagtgcttgagaagag 407 54
Vimentina ttcagagagaggaagccgaaaactttaagggcatccacttcacag 422 56
c-kit (CD117) ttcagcgagagttaatgattctgtgtattcacataaacattaaatg 400 50
Thy-1 (CD90) aaagaagcacgtgctctttggcactcagagaagtaggatctctg 379 56
GATA-4 cacaagatgaacggcatcaaccagacatcgcactgactgagaa 439 56
GAPDH acaactttggtatcgtggaaaaattcgttgtcataccagg 458 50
Figure 1a. Expression levels of certain liver specific genes and the catalytic subunit of 
the telomerase enzyme as determined by RT-PCR.
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RESULTS
Molecular characterisation
The RTtPCR analysis shows that the stemtlike cells 
isolated from the hepatocellular carcinoma biopsy ext
press markers proven to be specific to early hepatic 
progenitors (Figure 1a). Betat2 microglobulin and 
GAPDH were used as controls. Darwinian selection 
of the cancer stemtlike cell subpopulation was later 
on seen in culture, confirming the results found in 
the clinic after the initial tumoral relapse, when the 
disease continued to progress despite multimodal agt
gressive oncology treatments. The expression of stem 
celltspecific markers was also confirmed by immunot
cytochemistry staining, which proved the presence 
of the stem celltcharacteristic markers CD 90 and 
CD133 (Figures 1b, c).
Stem-like tumor cells are resistant to conven-
tional chemotherapy
Because rhodamine 123 uses the same pathways to pass 
through the membrane as conventional drugs used in 
oncologic treatments, by measuring the optical density 
(OD) of this fluorescent substance, we were able to det
termine indirectly whether the cell population isolated 
from HCC expresses the proteins responsable for mult
tidrug resistance. Hepatic cancer stem cells were comt
pared with both the HFL human fibroblast cell line and 
to MLS ovarian tumor cell line (Figure 2). 
To examine whether hepatic tumor cells possessed 
a hypothesized cancer stem cell chemoresistant phenot
type, we also assessed the sensitivity of the cells to cart
boplatin and doxorubicin under stem cell conditions. 
Compared with HFL fibroblasts and MLS tumor ovart
ian cells, both carboplatin and doxorubicin optical dent
sity IC50 values were greater (P<.05) (Figure 3). These 
results support a role for these stemtlike cells in hepatic 
cancer chemoresistance (i.e. failure to eradicate progenit
tors resulting in tumor regrowth).
Clonogenic survival after treatment
The concentration used was 0.5 μM, readily and safely 
acheivable in patients. Apart from the previously proven 
resistance to very high concentrations of carboplatin and 
doxorubicin, cancer stem cells are also resistant to both 
therapeutic treatments with sorafenib and the modified 
PIAF regimen, with capecitabine replacing 5tfluorourat
cil. Normal stem cells are also resistant, in comparison 
with the differentiated tumor cell line HepG2. When 
adding ATO prior to treatment, the results show a ret
duced survival of tumor cells in a dosetdependent mant
ner, at 24, 48 hours and 72 hours (Figures 4a, b, c). Our 
results demonstrate that the ATO + PIAF regimen is 
the best combination chemotherapy for hepatocellular 
carcinoma, superior to both tyrosine kinase inhibitor 
and only PIAF regimen, in all theree cell lines (P<.05).
DISCUSSION
HCC has been a very common disease in Far East Asia, 
South Africa and SubtSaharan Africa for several det
B C
Figure 1b,c. Immunocytochemistry stainings demonstrating that 
the cells are positive for both CD133 (×100) (B) and for CD 90 
(×100) (C).
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from one progenitor cancer stem cell, modern oncology 
should focus on targeting this biological entity in order 
to aim for a cure in hepatic cancer. 
As we previously mentioned, the failure of existing 
treatments for cancer has been recently been attributed 
to the existence of CSCs, which are difficult to kill using 
current drugs because of their chemoresistant propert
ties as well as their ability to stimulate neoangiogenesis. 
Differentiation therapy is a statetoftthetart concept in 
oncology, only recently reported for leukemia and pract
tically inexistent for solid tumors. Our study is the first 
in the country and one of the first in international intert
nal medicine reporting the chemosensitization capacity 
of arsenic trioxide for hepatocellular carcinoma, supt
porting the protdifferentiation hypothesis in anticancer 
research.  
Arsenium, used in medicine for more than 2400 
years,14,15 was approved by the United States Food 
and Drug Administration for use in the treatment of 
relapsed/refractory acute promyeolocytic leukemia bet
cause it downregulates Bclt2 levels, inteferes with the 
Notch signaling pathway and promotes differentiation 
followed by apoptosis, arresting cells either in G2M or 
both G1 and G2M.16 We also show that low concent
trations of ATO lead to morphologic differentiation 
and differentiationtassociated cytochemical features, 
like increased sensitivity to cytostatic drugs. ATO may 
have stimulated stem cell differentiation (both normal 
hepatic stem cells and CSC), thus sensitizing them to 
chemotherapy. The two stem cell lines are compared 
with the HepG2 nontstem liver cancer cell line to int
vestigate the differences between differentiated and 
more anaplastic cells, confirming that an efficient treatt
ment for liver cancer should target the stem cell pool, 
as the other cancerous cells will eventually undergo 
apoptosis. Because there are fewer CSC in the G0 state, 
conventional chemotherapy will be more efficient in the 
treatment of nontsurgical HCC, but further in vivo ext
periments on laboratory animals and an analysis of abt
sorbtion rate and side effects are required before we can 
administer arsenic trioxide to patients diagnosed with 
liver cancer.
 In conclusion, human HCC is composed of a hit
erarchy of mixed tumor cells with different biological 
properties, including tumortinitiating cells or cancer 
stem cells. CSCs, with selftrenewal and differentiation 
capability, constitutes a small population of this hierart
chy and are thought to give rise to tumor heterogenity 
and chemoresistance. Thus, CSC eradication is critical 
to achieve stable remission or even a cure for aggresive 
malignancies such as liver cancers. One way to eradicate 
CSCs being obtained through stem cell differentiation 
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Figure 2. After culture for three hours in a humidified atmosphere at 37°C and 5% 
carbon dioxide, hepatic cancer cells had the capability for accelerated efflux from the 
cytoplasma of fluorescent rhodamine 123 using the ABC family proteins. The fibroblasts 
also expressed, to some extent, this characteristic but the ovarian tumor cells were not 
resistant, failing to eliminate most of the dye. CSC: cancer stem cells, HFL: human fetal 
lung fibroblasts, MLS: human ovarian tumor cell line 
MLS
cades because of the high prevalence of hepatitis B vit
ral (HBV) infection and aflatoxin exposure. In the last 
few years, a sharp increase of HCC incidence in North 
America, European Union and Japan has been reported 
due to hepatitis C viral (HCV) infection, alcohol abuse 
and nontalcoholic fatty liver disease. Liver cancer is the 
forth most common neoplasia and the third most comt
mon cause of cancertrelated death in the world, with 
incidence rates varying from 2 per 100 000 population 
in the US to 80 per 100 000 population in China, with 
an overall 5tyear survival rate lower than 5%.10t11
The best longtterm treatment for patients with HCC 
is orthotopic liver transplantation, in the case of which 
eligibility is limited to those meeting the Milan criteria 
(one nodule <5 cm or maximum three nodules <3 cm 
each) with a 5tyear survival rate after trasnplantation at 
about 70%, but tumor progression while waiting for a 
matched donor is the most common cause of droptout 
from the transplant list.12 Thus, the most common treatt
ment, including neoadjuvant treatment for those on the 
transplant list, is intended to control the progression by 
methods that include transarterial chemoembolization, 
selective internal radiotherapy, radiofrequency ablation 
and percutaneous injection with either ethanol or acetic 
acid. This treatment is not curative, but reduces the vit
able tumor volume and slows cancer progression for a 
while, until resistance appears and treatment becomes 
useless. The mechanism of HCC resistance is complex, 
depending on the plasticity of the cell of origin—oft
ten a dysfunctional progenitor or cancer stem cell.13 As 
most HCC are clonal and thus considered to originate 
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using protdifferentiation agents such as arsenic trioxide, 
already used in the clinic for hematologic malignancies. 
Our results demonstrate for the first time this hypothesis 
in the potential treatment of hepatocellular carcinoma. 
This data is critical to realizing the potential for synergy 
between arsenic trioxide agent chemotherapeutic protot
cols, such as PIAF, in hope to provide in the near future 
an enhaced benefit for liver cancer treatment. 
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Figure 3. Liver CSC, under stem cell conditions, were highly resistant to conventional chemotherapies. Cells were treated with 5 µg/mL 
carboplatin and 5 µg/mL doxorubicin for 24 hours (a) and for 48 hours (b). Hepatic tumor cells (both treated and the control group) 
were compared with fibroblasts and ovarian tumor cells and cell survival was determined by MTT assay.
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Figure 4a. Survival curves for cancer stem cells and PIAF 
combination chemotherapy regimen.
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Figure 4b. Survival curves for normal stem cells and PIAF 
combination chemotherapy regimen.
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Figure 4c. Survival curves for differentiated hepatic tumor cell 
line HepG2 and PIAF combination chemotherapy regimen.
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